$1.185 Billion: The DuPont-Chemours PFAS Settlement and the Cost of a Half-Century of Fluorochemical Manufacturing
By Paul E. Rosenfeld, M.S., Ph.D., Principal Environmental Chemist, RoseyFields LLC, Santa Monica, California
A settlement sized to a manufacturing legacy
In June 2023, chemical manufacturers DuPont de Nemours, Corteva, Inc., and The Chemours Company agreed to establish a $1.185 billion settlement fund to resolve a large portion of multidistrict litigation alleging PFAS contamination of drinking water nationwide. Dr. Paul E. Rosenfeld, M.S., Ph.D. of RoseyFields LLC collected and analyzed the underlying exposure data supporting this litigation.
Why three separate corporate entities share liability
DuPont, Corteva, and Chemours’ joint participation in the settlement reflects a corporate history in which Chemours was spun off from DuPont in 2015 specifically holding the legacy fluorochemicals business, and Corteva was later separated as DuPont’s agricultural division, meaning liability for decades of historical PFAS manufacturing had to be allocated across corporate successors rather than a single continuously operating company.
PFOA manufacturing as the historical source
DuPont’s Washington Works facility in West Virginia manufactured PFOA (perfluorooctanoic acid) for use in Teflon and related fluoropolymer production for decades, releasing PFOA into air, soil, and groundwater that ultimately contaminated drinking-water supplies serving communities in West Virginia and Ohio, the historical exposure pattern underlying much of the resulting nationwide PFAS litigation.
How public water providers, not just residents, became plaintiffs
As in other major PFAS litigation, the DuPont-Chemours settlement resolved claims brought substantially by public water providers seeking reimbursement for PFAS testing and treatment costs, a claimant structure paralleling the atrazine and MTBE settlements and reflecting the reality that utilities bear the immediate financial burden of responding to contamination affecting their source water.
The scientific record connecting PFOA to specific health outcomes
Much of the epidemiological evidence linking PFOA to specific health outcomes, including kidney and testicular cancer, thyroid disease, ulcerative colitis, and pregnancy-induced hypertension, originates from the C8 Science Panel, an independent epidemiological research effort established as part of earlier DuPont litigation specifically to study a highly exposed Mid-Ohio Valley community (C8 Science Panel).
Fate and transport modeling across multiple exposure media
Because DuPont’s historical PFOA releases occurred through both air emissions and direct wastewater discharge, the exposure reconstruction underlying this litigation required combining air deposition modeling with groundwater fate-and-transport modeling, tracking how the same chemical reached the same communities through more than one environmental pathway simultaneously.
The current regulatory endpoint for PFOA in drinking water
EPA’s 2024 PFAS National Primary Drinking Water Regulation sets a Maximum Contaminant Level of 4.0 parts per trillion for PFOA, an extraordinarily low regulatory threshold that reflects the cumulative epidemiological and toxicological evidence, including findings from the C8 Science Panel, developed substantially in litigation connected to the very manufacturing history at issue in this settlement (US EPA, 2024).
A settlement that preserved state-level claims
The settlement advanced after revisions addressed state objections while preserving states’ rights to pursue separate claims, meaning the $1.185 billion fund resolved a substantial portion, but not the entirety, of DuPont, Corteva, and Chemours’ potential PFAS liability nationally.
Why manufacturing-source PFAS cases differ from AFFF-based cases
Unlike firefighting-foam PFAS litigation, where the exposure pathway traces to product use at a specific application site, manufacturing-source PFAS litigation like the DuPont matter traces exposure to a fixed production facility’s air emissions and wastewater discharge, requiring a different, facility-specific fate-and-transport model than the multi-site AFFF application pattern addressed in other PFAS matters (Bells, 2018).
The continuing significance of the C8 Science Panel’s legacy
Because the epidemiological findings from the C8 Science Panel now underpin both individual litigation and national regulatory standards, that research program’s methodology and findings will likely remain the central scientific reference point for PFOA-related litigation for years to come. For more on Dr. Rosenfeld’s PFAS exposure assessment work, visit RoseyFields.com.
References
1. In re E.I. du Pont de Nemours & Co. C-8 Personal Injury Litigation and related PFAS public water system multidistrict litigation; DuPont/Corteva/Chemours settlement approved 2023.
2. RoseyFields LLC. $1.185 Billion DuPont PFAS Settlement. Santa Monica, CA: RoseyFields LLC; 2026.
3. C8 Science Panel. Probable Link Reports: PFOA and Human Disease. Mid-Ohio Valley, WV/OH: C8 Science Panel; 2011-2012.
4. US Environmental Protection Agency. PFAS National Primary Drinking Water Regulation. 40 CFR Parts 141 and 142. Fed Regist. 2024;89(81):32532-32757.
5. Bells RL, et al. v The 3M Company, et al. Case No. 1:16-cv-02531-RBJ (D Colo).
6. US Environmental Protection Agency. Human Health Toxicity Assessment for Perfluorooctanoic Acid (PFOA) and Related Compounds. Washington, DC: US EPA; 2024.
7. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Perfluoroalkyls. Atlanta, GA: US Department of Health and Human Services; 2021.
8. Rosenfeld PE, Spaeth KR, Remy LL, Byers V, Muerth SA, Hallman RC, Summers-Evans J, Barker S. Perfluoroalkyl substances exposure in firefighters: sources and implications. Environ Res. 2023;220:115164.
9. Rosenfeld PE. Fate, Transport and Persistence of PFOA and Related Chemicals. Mealey’s C8/PFOA Science, Risk & Litigation Conference; October 24-25, 2005; Philadelphia, PA.
10. US Environmental Protection Agency. Toxic Substances Control Act (TSCA) PFAS Reporting Rule. 40 CFR Part 705.
11. US Environmental Protection Agency. Per- and Polyfluoroalkyl Substances (PFAS): Proposed PFOA and PFOS Compliance Extension Rule. Washington, DC: US EPA; 2026.
12. Rosenfeld PE. RoseyFields LLC: PFAS Fate, Transport, and Exposure Assessment. Santa Monica, CA: RoseyFields LLC; 2026.
13. US Environmental Protection Agency. Revisions to the Guideline on Air Quality Models. 40 CFR Part 51, Appendix W. Fed Regist. 2017;82(10):5182-5235.
14. US Environmental Protection Agency. Toxicological Review of Benzene (Noncancer Effects). Integrated Risk Information System (IRIS). Washington, DC: US EPA; 2003.